Compare Johnson & Johnson (JNJ) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Keysight Technologies Inc — how do they compare? Johnson & Johnson trades at $256.22 (market cap $618.09B), while Keysight Technologies Inc trades at $380.01 (market cap $63.79B). The key difference: Johnson & Johnson is far larger — about 9.7× Keysight Technologies Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while Keysight Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Keysight Technologies Inc for 56 Days on average.
| JNJ | KEYS | |
|---|---|---|
Market Cap | $618.09B | $63.79B |
Volume | 6,050,983 | 1,435,384 |
Sector | Health | Technology |
52-Week High | $278.43 | $387.90 |
52-Week Low | $186.00 | $159.49 |
Typical Hold Time | 129 Days | 56 Days |
Enterprise Value | $646.37B | $63.93B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $258.45, up 1.44% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and robust cash flow. Analyst consensus is bullish with a $286.53 price target, though technical indicators show resistance near $260. Recent news highlights pipeline strength including Icotyde's potential $4.5B peak sales.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and competitive pressures. The stock presents value near current levels with 10.7% upside to consensus target, though technical weakness suggests potential near-term consolidation. Long-term growth drivers include oncology portfolio and Ottava surgical system development.
Keysight Technologies (KEYS) trades at $381.49, down 1.65% on the day, amid strong fundamental performance with Q2 2026 EPS beating estimates at $3.07. The stock shows a bullish technical trend, trading near the pivot point of $380 with support at $377. Revenue for 2025 reached $5.38B, with net income of $850M, and the company is actively advancing in AI infrastructure and 6G testing, as highlighted in recent product launches and collaborations.
Outlook remains positive with a consensus price target of $416.63, representing a 9.2% upside, supported by accelerating earnings and strong AI demand. Risks include high valuation multiples, such as a P/E of 51.61, and supply constraints that may limit near-term revenue conversion despite surging orders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
